Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
TenX BioPharma grants Emergent BioSolutions rights to zanolimumab

TenX BioPharma grants Emergent BioSolutions rights to zanolimumab

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011

Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Ipilimumab and bevacizumab drugs effective in treating metatastic melanoma

Ipilimumab and bevacizumab drugs effective in treating metatastic melanoma

IMUC, BioWa sign license deal to develop ADCC enhanced antibodies for cancer

IMUC, BioWa sign license deal to develop ADCC enhanced antibodies for cancer

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

Symphogen's rozrolimupab Phase 2 data to be presented at European Hematology Association meeting

Symphogen's rozrolimupab Phase 2 data to be presented at European Hematology Association meeting

Symphogen's Sym004 Phase 1 data on advanced solid tumors to be presented at ASCO 2011

Symphogen's Sym004 Phase 1 data on advanced solid tumors to be presented at ASCO 2011

Eculizumab effective for treating hemolytic-uremic syndrome from EHEC

Eculizumab effective for treating hemolytic-uremic syndrome from EHEC

Centocor Ortho Biotech, AVEO sign license deal to develop, commercialize RON-targeted antibodies

Centocor Ortho Biotech, AVEO sign license deal to develop, commercialize RON-targeted antibodies

YM announces updates on nimotuzumab clinical development program

YM announces updates on nimotuzumab clinical development program

Transgenomic secures exclusive license from Montefiore for cancer predictive markers

Transgenomic secures exclusive license from Montefiore for cancer predictive markers

Bayer, Epitomics enter service agreement for antibody technology

Bayer, Epitomics enter service agreement for antibody technology

Two Novartis ACZ885 Phase III trial data in severe gouty arthritis to be presented at EULAR 2011

Two Novartis ACZ885 Phase III trial data in severe gouty arthritis to be presented at EULAR 2011

Inotuzumab ozogamicin achieves over 50% response rate against acute lymphoblastic leukemia

Inotuzumab ozogamicin achieves over 50% response rate against acute lymphoblastic leukemia

Micromet's blinatumomab data to be presented at two upcoming medical meetings

Micromet's blinatumomab data to be presented at two upcoming medical meetings

Lilly Phase I multiple myeloma study affirms potential of LY2127399-bortezomib combination

Lilly Phase I multiple myeloma study affirms potential of LY2127399-bortezomib combination

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Data from Seattle Genetics' brentuximab vedotin, SGN-75 programs to be presented at ASCO 2011

Data from Seattle Genetics' brentuximab vedotin, SGN-75 programs to be presented at ASCO 2011

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.